HIV trial ‘could be answer for women’

2012-04-18 10:23

Sydney – Two microbicides clinical trials – one of which is aimed at providing women with a tool to prevent HIV infection without relying on their partners – are about to start in South Africa.

The first trial involves a vaginal ring which will contain an antiretroviral (ARV) drug and the other is an ARV-based rectal gel which will be tested by men who have sex with men.

The ring trial is expected to start in three sites in South Africa in  July or August. The rectal microbicides trial is set to launch early next year.

The ring, which will be made of silicone, will contain a commonly used ARV drug, dapivirine. The drug will continuously release into the vaginal tissue for 28 days. After four weeks it will be removed by the user and replaced with a new one.

The study will be conducted over two years and the result are expected in early 2015.

Said Zeda Rosenberg of the International Partnership for Microbicides: “This is an exciting initiative and if it works it could be the answer that women have been looking for.”

Scientists are hoping that the ring would prevent HIV transmission from men to women during sex.

It is hoped that when the HI virus infects the woman’s healthy cells during sex and later tries to multiply it will be interrupted by the ARVs present in the vaginal tissue.

Over 34 million people are living with HIV in the world and half of them are women. It is further estimated that two-thirds of the 17 million HIV positive women are living in Southern Africa.

Said Rosenberg: “The majority of women acquire HIV through heterosexual intercourse and the only way to prevent further infections is to provide women with a tool they can use without relying on their partners.”

The rectile microbicides gel trial will only recruit men in South Africa at first. Women will be recruited in follow-up trials. Participants will use an ARV-based gel with 1% of the drug tenofovir.

Said Ian McGowan of the Microbicides Trials Network: “It would be unrealistic to exclude women from the trial because they have anal sex as well.

“The gel has been used in several vaginal microbicides trial before and its safety and acceptability in the rectum has been proven. Although at first there were gastrointestinal side effects, we have sorted this out,” he said.

The rectal trial will involve 186 men and transgender women from South Africa, Thailand, Peru and the United States.

Results are expected at the end of 2014.

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions. publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.